Cargando…

DPP4 as a Potential Candidate in Cardiovascular Disease

The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Si-Yu, Kong, Xiang-Quan, Zhang, Ke-Fan, Luo, Shuai, Wang, Feng, Zhang, Jun-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488155/
https://www.ncbi.nlm.nih.gov/pubmed/36147690
http://dx.doi.org/10.2147/JIR.S380285
_version_ 1784792598457614336
author Chen, Si-Yu
Kong, Xiang-Quan
Zhang, Ke-Fan
Luo, Shuai
Wang, Feng
Zhang, Jun-Jie
author_facet Chen, Si-Yu
Kong, Xiang-Quan
Zhang, Ke-Fan
Luo, Shuai
Wang, Feng
Zhang, Jun-Jie
author_sort Chen, Si-Yu
collection PubMed
description The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy.
format Online
Article
Text
id pubmed-9488155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94881552022-09-21 DPP4 as a Potential Candidate in Cardiovascular Disease Chen, Si-Yu Kong, Xiang-Quan Zhang, Ke-Fan Luo, Shuai Wang, Feng Zhang, Jun-Jie J Inflamm Res Review The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy. Dove 2022-09-16 /pmc/articles/PMC9488155/ /pubmed/36147690 http://dx.doi.org/10.2147/JIR.S380285 Text en © 2022 Chen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Chen, Si-Yu
Kong, Xiang-Quan
Zhang, Ke-Fan
Luo, Shuai
Wang, Feng
Zhang, Jun-Jie
DPP4 as a Potential Candidate in Cardiovascular Disease
title DPP4 as a Potential Candidate in Cardiovascular Disease
title_full DPP4 as a Potential Candidate in Cardiovascular Disease
title_fullStr DPP4 as a Potential Candidate in Cardiovascular Disease
title_full_unstemmed DPP4 as a Potential Candidate in Cardiovascular Disease
title_short DPP4 as a Potential Candidate in Cardiovascular Disease
title_sort dpp4 as a potential candidate in cardiovascular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488155/
https://www.ncbi.nlm.nih.gov/pubmed/36147690
http://dx.doi.org/10.2147/JIR.S380285
work_keys_str_mv AT chensiyu dpp4asapotentialcandidateincardiovasculardisease
AT kongxiangquan dpp4asapotentialcandidateincardiovasculardisease
AT zhangkefan dpp4asapotentialcandidateincardiovasculardisease
AT luoshuai dpp4asapotentialcandidateincardiovasculardisease
AT wangfeng dpp4asapotentialcandidateincardiovasculardisease
AT zhangjunjie dpp4asapotentialcandidateincardiovasculardisease